Form 4: Atea Pharmaceuticals Director Barbara Gayle Duncan Reports Acquisition of Stock Options and Restricted Stock Units

Director Barbara Gayle Duncan reported acquiring stock options and restricted stock units in Atea Pharmaceuticals, Inc. on June 21, 2024.

Summary

• Barbara Gayle Duncan, a director of Atea Pharmaceuticals, Inc., filed a Form 4 on June 21, 2024.
• The report details the acquisition of derivative securities, specifically restricted stock units and stock options.
• Duncan acquired 29,600 restricted stock units that convert into common stock on a one-for-one basis.
• These restricted stock units vest on the earlier of the next annual meeting of the Issuer's stockholders or the first anniversary of the grant date, contingent upon continued service.
• Additionally, Duncan acquired 41,200 stock options with an exercise price of $3.44.
• The stock options vest in twelve substantially equal monthly installments following June 21, 2024, and will be fully vested on the first anniversary of the grant date, subject to continued service.
• The expiration date for the stock options is June 20, 2034.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It reflects routine transactions by a company director.

Positives

• The acquisition of stock options and restricted stock units by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedules for both the restricted stock units and stock options are contingent upon the Reporting Person's continued service.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The acquisition of stock options and restricted stock units by a director may signal confidence to shareholders.

Key Dates